Objective： To evaluate the therapeutic effects and safety of the XIA＇s No.1 Sleeping Prescription for the treatment of insomnia of the deficiency type. Methods： 120 cases conformed to the diagnostic criteria of the...Objective： To evaluate the therapeutic effects and safety of the XIA＇s No.1 Sleeping Prescription for the treatment of insomnia of the deficiency type. Methods： 120 cases conformed to the diagnostic criteria of the Chinese Classification of Mental Disorders-Version 3 （CCMD-3） and were diagnosed as having insomnia of the deficiency type were divided randomly into a treatment group and a control group, 60 cases in each group. The treatment group was treated with the XIA＇s No.1 Sleeping Prescription, while the control group was given estazolam （ling） for 6 weeks. The Athens Insomnia Scale （AIS） was used to evaluate the clinical therapeutic effects, while the treatment emergent symptom scale （TESS） was used to evaluate adverse reactions. Results： The total effective rate of the treatment group （80%） was higher than that of the control group （70%）, but with no significant difference （P〉0.05）. The effective rate for long-term insomnia was 77.8% in the treatment group and 52.4% in the control group, with a significant difference between the two groups （P〈0.05）. The adverse reactions shown in the treatment group were obviously fewer and milder than those in the control group. Conclusion： The XIA＇s No. 1 Sleeping Prescription is effective for insomnia of the deficiency type and with no obvious toxic side effects.展开更多
文摘Objective： To evaluate the therapeutic effects and safety of the XIA＇s No.1 Sleeping Prescription for the treatment of insomnia of the deficiency type. Methods： 120 cases conformed to the diagnostic criteria of the Chinese Classification of Mental Disorders-Version 3 （CCMD-3） and were diagnosed as having insomnia of the deficiency type were divided randomly into a treatment group and a control group, 60 cases in each group. The treatment group was treated with the XIA＇s No.1 Sleeping Prescription, while the control group was given estazolam （ling） for 6 weeks. The Athens Insomnia Scale （AIS） was used to evaluate the clinical therapeutic effects, while the treatment emergent symptom scale （TESS） was used to evaluate adverse reactions. Results： The total effective rate of the treatment group （80%） was higher than that of the control group （70%）, but with no significant difference （P〉0.05）. The effective rate for long-term insomnia was 77.8% in the treatment group and 52.4% in the control group, with a significant difference between the two groups （P〈0.05）. The adverse reactions shown in the treatment group were obviously fewer and milder than those in the control group. Conclusion： The XIA＇s No. 1 Sleeping Prescription is effective for insomnia of the deficiency type and with no obvious toxic side effects.
